• Je něco špatně v tomto záznamu ?

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

M Delforge, E Terpos, PG Richardson, O Shpilberg, NK Khuageva, R Schlag, MA Dimopoulos, M Kropff, I Spicka, MT Petrucci, OS Samoilova, MV Mateos, H Magen-Nativ, H Goldschmidt, DL Esseltine, DS Ricci, K Liu, W Deraedt, A Cakana, de Velde H van,...

. 2011 ; 86 (5) : 372-384.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17015124

Grantová podpora
NT12215 MZ0 CEP - Centrální evidence projektů

OBJECTIVES: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment. METHODS: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m(2) , days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, days 1, 8, 22, 29, cycles 5-9, plus melphalan 9mg/m(2) and prednisone 60mg/m(2) , days 1-4, cycles 1-9; N=344) or MP alone (N=338). RESULTS: Rates of bisphosphonates use during treatment (73% vs. 82%), progression because of worsening bone disease (3% vs. 11%), and requirement for subsequent radiotherapy (3% vs. 8%) were lower with VMP vs. MP. Median maximum ALP increase was significantly higher with VMP vs. MP overall (49.7% vs. 30.3%, P=0.029), and higher by response group (complete response [CR]: 68.7% vs. 43.9%; partial response [PR]: 41.5% vs. 31.2%). Greater maximum ALP increase was strongly associated with achievement of CR (P<0.0001) and CR/PR (P<0.01). Median DKK-1 decreased with VMP by 694.4pg/mL and increased with MP by 1273.3pg/mL from baseline to day 4 (P=0.0069). Available radiologic data revealed evidence of bone healing in 6/11 VMP-treated patients, who achieved best responses of three CR, one PR, and two stable disease. CONCLUSIONS: These results suggest a positive effect of bortezomib on bone metabolism and potentially bone healing in myeloma. Copyright © 2011 John Wiley & Sons A/S.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17015124
003      
CZ-PrNML
005      
20190104104437.0
007      
ta
008      
170425s2011 xxkd f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1600-0609.2011.01599.x $2 doi
035    __
$a (PubMed)21366694
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Delforge M $u Delforge, Michel. Myeloma Study Group, Belgian Hematological Society, Belgium. michel.delforge@uzleuven.be
245    10
$a Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma / $c M Delforge, E Terpos, PG Richardson, O Shpilberg, NK Khuageva, R Schlag, MA Dimopoulos, M Kropff, I Spicka, MT Petrucci, OS Samoilova, MV Mateos, H Magen-Nativ, H Goldschmidt, DL Esseltine, DS Ricci, K Liu, W Deraedt, A Cakana, de Velde H van, Miguel JF San
520    9_
$a OBJECTIVES: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment. METHODS: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m(2) , days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, days 1, 8, 22, 29, cycles 5-9, plus melphalan 9mg/m(2) and prednisone 60mg/m(2) , days 1-4, cycles 1-9; N=344) or MP alone (N=338). RESULTS: Rates of bisphosphonates use during treatment (73% vs. 82%), progression because of worsening bone disease (3% vs. 11%), and requirement for subsequent radiotherapy (3% vs. 8%) were lower with VMP vs. MP. Median maximum ALP increase was significantly higher with VMP vs. MP overall (49.7% vs. 30.3%, P=0.029), and higher by response group (complete response [CR]: 68.7% vs. 43.9%; partial response [PR]: 41.5% vs. 31.2%). Greater maximum ALP increase was strongly associated with achievement of CR (P<0.0001) and CR/PR (P<0.01). Median DKK-1 decreased with VMP by 694.4pg/mL and increased with MP by 1273.3pg/mL from baseline to day 4 (P=0.0069). Available radiologic data revealed evidence of bone healing in 6/11 VMP-treated patients, who achieved best responses of three CR, one PR, and two stable disease. CONCLUSIONS: These results suggest a positive effect of bortezomib on bone metabolism and potentially bone healing in myeloma. Copyright &#xa9; 2011 John Wiley & Sons A/S.
590    __
$a bohemika - dle Pubmed
650    02
$a senioři $7 D000368
650    02
$a senioři nad 80 let $7 D000369
650    02
$a alkalická fosfatasa $x krev $7 D000469
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    02
$a biologické markery $x krev $7 D015415
650    02
$a nemoci kostí $x etiologie $7 D001847
650    02
$a nemoci kostí $7 D001847
650    12
$a remodelace kosti $x účinky léků $7 D016723
650    02
$a kyseliny boronové $x aplikace a dávkování $7 D001897
650    02
$a bortezomib $7 D000069286
650    02
$a buněčná diferenciace $7 D002454
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a mezibuněčné signální peptidy a proteiny $x krev $7 D036341
650    02
$a mužské pohlaví $7 D008297
650    02
$a melfalan $x aplikace a dávkování $7 D008558
650    02
$a lidé středního věku $7 D008875
650    02
$a Multiple Myeloma $x co [Complications]
650    12
$a Multiple Myeloma $x dt [Drug Therapy]
650    02
$a mnohočetný myelom $x patofyziologie $x patologie $7 D009101
650    02
$a osteoblasty $7 D010006
650    02
$a prednison $x aplikace a dávkování $7 D011241
650    02
$a pyraziny $x aplikace a dávkování $7 D011719
650    02
$a adjuvantní radioterapie $7 D018714
700    1_
$a Terpos E
700    1_
$a Richardson PG
700    1_
$a Shpilberg O
700    1_
$a Khuageva NK
700    1_
$a Schlag R
700    1_
$a Dimopoulos MA
700    1_
$a Kropff M
700    1_
$a Špička, Ivan, $d 1960- $7 jn20001103644
700    1_
$a Petrucci MT
700    1_
$a Samoilova OS
700    1_
$a Mateos MV
700    1_
$a Magen-Nativ H
700    1_
$a Goldschmidt H
700    1_
$a Esseltine DL
700    1_
$a Ricci DS
700    1_
$a Liu K
700    1_
$a Deraedt W
700    1_
$a Cakana A
700    1_
$a van de Velde H
700    1_
$a San Miguel JF
773    0_
$t European Journal of Haematology $g Roč. 86, č. 5 (2011), s. 372-384 $p Eur J Haematol $x 0902-4441 $w MED00001620
773    0_
$p Eur J Haematol $g 86(5):372-84, 2011 May
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20170425151719 $b ABA008
991    __
$a 20190104104632 $b ABA008
999    __
$a ok $b bmc $g 1202101 $s 975908
BAS    __
$a 3
BMC    __
$a 2011 $b 86 $c 5 $d 372-384 $x MED00001620 $i 0902-4441 $m European journal of haematology
GRA    __
$a NT12215 $p MZ0
LZP    __
$a NLK 2015-B/lp

Najít záznam

Citační ukazatele

Možnosti archivace